The use of ursodeoxycholic acid for intrahepatic cholestasis of pregnancy does not reduce adverse perinatal outcomes and should be reconsidered, UK researchers say.

The pregnancy liver disorder is associated with increased rates of stillbirth, preterm birth and admission to the neonatal unit.